Polaryx Therapeutics, Inc.
PLYX
$3.62
-$0.88-19.56%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
2/10/2026
-
Globe Newswire
2/5/2026
-
Globe Newswire
2/3/2026
-
Globe Newswire
2/2/2026
-
Globe Newswire
1/30/2026
-
Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
--
Total Debt (Q)
--
Total Liabilities (Q)
--
Book Value Per Share (Q)
--
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Period Date
Next Filing
(est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
--
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
201 940 7236
Address
South Tower
140 E Ridgewood Avenue - Suite 415
Paramus, NJ 07652
140 E Ridgewood Avenue - Suite 415
Paramus, NJ 07652
Country
Year Founded
Business Description
Sector
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical...
more